SPRY ARS Pharmaceuticals, Inc.
Legal ·
AptarGroup and Aptar France sued ARS Pharmaceuticals and ARS Pharmaceuticals Operations in March 2025. The company's separate antitrust suit against AptarGroup was moved to New York in July 2026.
A stockholder sued the company and unnamed current and former officers in the Southern District of California on August 5, 2026. A pharmacy filed a separate fax-advertising class action in July.
ARS Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of neffy, a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions, including anaphylaxis. The company says neffy is the first and only FDA and European Commission-approved needle-free epinephrine product, and that it also has approvals in the U.K., Japan, Australia and China. The text describes it as the first new delivery method for epinephrine in more than 35 years. neffy uses an absorption enhancer called Intravail. The FDA approved neffy 2 mg in August 2024 for adults and children who weigh 30 kg or greater, and approved neffy 1 mg in March 2025 for patients four years of age and older who weigh 15 kg to less than 30 kg. The company estimates there are approximately 40 million people in the U.S. who experience Type I allergic reactions, and that approximately 6.5 million of those with severe reactions were prescribed an epinephrine autoinjector. It runs a direct sales force of 106 individuals to commercialize neffy.
| Product or program | What it is | Stage |
|---|---|---|
| neffy | Needle-free intranasal epinephrine for Type I allergic reactions and anaphylaxis | approved |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $84.3 million | $89.1 million |
| Research and development | $13.2 million | $19.6 million |
| Net income (loss) | -$171.3 million | $8.0 million |
| Cash from operations | -$170.9 million | $13.5 million |
| Cash and equivalents | $41.3 million | $50.8 million |
| Short-term investments | $203.7 million | $263.2 million |
Our latest story on this, dated Aug 13, 2026: "ARS Pharmaceuticals faces securities class action over neffy insurance coverage timeline". The story links the filing or release it is based on. Read the story.
ARS Pharmaceuticals, Inc. trades under the ticker SPRY on NASDAQ.
ARS Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for ARS Pharmaceuticals, Inc. is 1671858. Its filings are on SEC EDGAR.
99,447,343 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Our directory records ARS Pharmaceuticals, Inc. under United States.
Our directory classifies ARS Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ARS Pharmaceuticals, Inc. is US82835W1080.
aibio.space lists ARS Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
ARS Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of neffy, a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions, including anaphylaxis. The company says neffy is the first and only FDA and European Commission-approved needle-free epinephrine product, and that it also has approvals in the U.K., Japan, Australia and China.
neffy: Needle-free intranasal epinephrine for Type I allergic reactions and anaphylaxis Stage: approved.
$84.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
ARS Pharmaceuticals, Inc. reported a net loss of $171.3 million for the fiscal year ended Dec 31, 2025, and used $170.9 million of cash in operations, per its annual report to the SEC.
$13.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio